Last reviewed · How we verify

NCT04043026: RALiC

The Effects of Renal Function and Atrial Fibrillation on Lipoproteins and Clot Structure/Function

Terminated Last updated 8 August 2022
What this trial tests

trial testing Statin in Atrial Fibrillation in 56 participants. Terminated before completion.

Timeline
26 September 2019
Primary endpoint
1 August 2022
1 August 2022

Quick facts

Lead sponsorUniversity of Liverpool
StatusTerminated
Study typeOBSERVATIONAL
Enrollment56
Start date26 September 2019
Primary completion1 August 2022
Estimated completion1 August 2022
Sites2 locations across United Kingdom

Drugs / interventions tested

Conditions studied

Sponsor

University of Liverpool

Who can join

18 and older, any sex, with Atrial Fibrillation or Chronic Kidney Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is designed to investigate the role of lipids/lipoproteins as a potential cause for the harmful changes seen in fibrin clot properties with renal dysfunction and atrial fibrillation

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Statin

Trials testing the same drug.

Other recruiting trials for Atrial Fibrillation

Currently open trials in the same condition.

Other University of Liverpool trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04043026.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing